Robert E Doss

US Patent:

8501420, Aug 6, 2013

Filed:

Aug 30, 2010

Appl. No.:

12/871056

Inventors:

Saul A. Datwyler - Evanston IL, US
Jessie W. Shih - Lake Forest IL, US
Robert C. Doss - Libertyville IL, US
Walter J. Keirans - Libertyville IL, US
Sudarshan Hebbar - Chicago IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

G01N 31/00

US Classification:

435 721, 435 4, 435 71, 4352879, 436501, 436518, 427287, 427337, 427338, 530300, 530350

Abstract:

The present invention relates to combinations of biomarkers and levels thereof that may be used, for example, in the determination of risk associated with the occurrence of a major adverse cardiac event (MACE) in a patient.

US Patent:

20070111326, May 17, 2007

Filed:

Mar 3, 2006

Appl. No.:

11/367126

Inventors:

David Sogin - Highland Park IL, US
Donald Laird - Mundelein IL, US
George Yu - Libertyville IL, US
Robert Doss - Libertyville IL, US

International Classification:

G01N 33/543

US Classification:

436518000

Abstract:

Method of measuring the quantity of a first proteinaceous specific binding partner (sbp) in a biological sample comprising detecting the binding of the first proteinaceous sbp with a labeled second proteinaceous sbp, wherein neither the first or second sbp is an antibody or fragment thereof, which is preferably a method of determining the amount of sFlt-1, particularly free sFlt-1, and the amount of PlGF, particularly free PlGF, in a sample, which is preferably used in a method of predicting risk of preeclampsia comprising comparing free PlGF to free sFlt-1.

US Patent:

20110229921, Sep 22, 2011

Filed:

Jun 9, 2010

Appl. No.:

12/796794

Inventors:

Robert C. Doss - Libertyville IL, US
Sudarshan Hebbar - Chicago IL, US

Assignee:

ABBOTT LABORATORIES - Abbott Park IL

International Classification:

C12Q 1/37

US Classification:

435 23

Abstract:

A method of prognosticating cadaveric kidney transplant function in a patient; a method of prognosticating cadaveric kidney transplant function in a patient diagnosed with DGF; a method of assessing risk of DGF in a patient, who has been diagnosed with EGF; and a kit comprising at least one component for assaying urine from a patient for NGAL and instructions for assaying the urine for NGAL and assessing cadaveric kidney transplant function or risk of DGF in the patient.